And in 2022, in a lawsuit brought by other plaintiffs in another Zantac case, a U.S. federal court judge ruled “the plaintiffs had no reliable evidence.” Sanofi acquired Zantac in 2017.
In 2022, a federal judge dismissed around 50,000 Zantac lawsuits after rejecting the plaintiffs’ scientific experts. Earlier ...
GSK has opted to settle a key lawsuit in its defence against ... including a US federal court ruling in December 2022 that found no reliable evidence that Zantac causes the alleged injuries ...
Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming ... got about 50,000 Zantac cases tossed from federal court in 2022, when a judge found that they ...
While the Company repeatedly claimed that scientific research did not support a correlation between Zantac ... August 15, 2022, thereby injuring investors further. What Is The Lawsuit About?
Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.